SWOG clinical trial number
SWOG-9429

Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma
Activated
08/15/1994
Closed
09/01/1995

Research committees

Lung Cancer

Publication Information Expand/Collapse

2019

Clinical prognostic model for older patients with advanced non-small cell lung cancer

AK Ganti;X Wang;T Stinchcombe;Y Wang;J Bradley;HJ Cohen;K Kelly;R Paulus;SS Ramalingam;EE Vokes;H Pang Journal of Geriatric Oncology Feb 20. pii: S1879-4068(18)30197-8. doi: 10.1016/j.jgo.2019.02.007. [Epub ahead of print]

PMid: PMID30797707

1998

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non-small cell lung cancer.

DH Lau;JJ Crowley;DR Gandara;MB Hazuka;KS Albain;B Leigh;WS Fletcher;KS Lanier;LW Keiser;RB Livingston Journal of Clinical Oncology 16(9):3078-3081

1997

A Southwest Oncology Group (SWOG) phase II trial: carboplatin and VP-16 with concurrent radiation for poor risk stage III non-small cell lung cancer.

DH Lau;D Gandara;M Hazuka;J Crowley;R Livingston Proc of the American Society of Clinical Oncology 16:449a(#1612)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
68%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open